Ignite Creation Date:
2024-05-05 @ 10:16 PM
Last Modification Date:
2024-10-26 @ 10:16 AM
Study NCT ID:
NCT01076179
Status:
COMPLETED
Last Update Posted:
2017-05-19
First Post:
2010-02-24
Brief Title:
Kaletra in Combination With Antiretroviral Agents
Sponsor:
AbbVie prior sponsor Abbott
Organization:
AbbVie
Study Overview
Official Title:
KALETRA in Combination With New Substances PROTEKT
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PROTEKT
Brief Summary:
The purpose of this study is to investigate the tolerability of Kaletra lopinavirritonavir in combination with new substances such as integrase inhibitors INIs C-C chemokine receptor type 5 CCR5 antagonists and new non-nucleoside reverse transcriptase inhibitors NNRTIs as there are many reasons intolerability complex resistant patterns or even personal reasons which may result in a change from the daily clinical routine and lead to the use of a newly approved antiretroviral agent in combination with Kaletra
Detailed Description:
This study was designed as a non-interventional observational study Kaletra was prescribed in the usual manner in accordance with the terms of the local market authorization with regards to dose population and indication as well as local guidelines
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None